Drug intelligence / Profile preview

PBO-326

Development stage: Phase 3
Lead developer: Probiomed
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

A rituximab biosimilar developed by Probiomed for indications including non-Hodgkin lymphoma (NHL) and rheumatoid arthritis (RA). It is a chimeric monoclonal antibody targeting CD20 on B lymphocytes, mediating B-cell depletion primarily through antibody-dependent cellular cytotoxicity and related immune effector functions. It has been marketed in Latin American countries such as Mexico, Bolivia, Chile, and Peru for NHL and RA. In at least one clinical protocol, PBO-326 was evaluated in alternating cycles with MabThera (rituximab) in patients with degenerative or neoplastic diseases.[7][4][1]

Brand names: Kikuzubam
Other names: rituximab biosimilar

Targets

CD20 (B-lymphocyte antigen CD20)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)

Beyond the preview

Go deeper on PBO-326.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PBO-326.

Explore the full profile